Molecular profile of the NF-κB signalling pathway in human colorectal cancer

Maria Dobre1, Bogdan Trandafir2,3, Elena Milanesi1

  • 1Victor Babes National Institute of Pathology, Bucharest, Romania.

Insights

This study investigated the NF-κB pathway in colorectal cancer (CRC), finding key gene and miRNA alterations. These findings could inform new miRNA-based therapies targeting CRC progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Inflammation Research

Background:

  • Colorectal cancer (CRC) progression is linked to inflammation and NF-κB pathway overactivation.
  • Targeting the NF-κB pathway is a potential therapeutic strategy for CRC.

Purpose of the Study:

  • To characterize the NF-κB signaling pathway's gene and miRNA expression profile in colorectal cancer.
  • To identify potential therapeutic targets within the NF-κB pathway for CRC treatment.

Main Methods:

  • Assessed expression of 84 NF-κB-related genes in tumoral (T), peritumoral (PT), and normal tissues from CRC patients.
  • Analyzed miRNA expression targeting dysregulated genes using bioinformatics and case-control analysis.
  • Validated gene expression in a larger cohort and correlated with tumor differentiation.

Main Results:

  • Identified 60 dysregulated NF-κB genes comparing T and normal tissues; 17 genes were dysregulated comparing T and PT tissues.
  • IL1B, CXCL8, IL1A, and CSF2 were significantly upregulated in T tissues.
  • Found decreased levels of RELA, NOD1, CASP8, BCL2L1, ELK1, and IKBKB in poorly differentiated tumors.
  • miR-182-5p was upregulated, and miR-10b-5p was downregulated in T tissues compared to PT and normal tissues.

Conclusions:

  • The NF-κB pathway is significantly altered in colorectal cancer, with specific genes and miRNAs showing differential expression.
  • Dysregulated genes like IL1B, CXCL8, IL1A, and CSF2, along with specific miRNAs, represent potential therapeutic targets.
  • Results support developing novel miRNA-based strategies to target key NF-κB pathway players in CRC.